In the adjuvant KATHERINE trial, early-stage HER2+ breast cancer patients who had residual tumor post-neoadjuvant treatment with trastuzumab and taxane chemotherapy were randomized to receive either 14 cycles of adjuvant T-DM1 or trastuzumab [10]. This evidence concerns the gene ERBB2 and neoplasm.